---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-343519"
form_type: "8-K"
ticker: "MREO"
cik: "0001719714"
company_name: "Mereo BioPharma Group plc"
filed_at: "2026-08-11T12:26:13+00:00"
generated_at: "2026-08-11T12:30:16.790903+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Mereo Q2 net loss narrows to $7M; Sentynl alvelestat option deal worth up to $475M

## Summary
- Q2 2026 net loss $7.0M vs $14.6M in Q2 2025; R&D down $3.6M to $1.8M.
- Cash $30.1M at June 30, 2026; runway into late-2027, excluding $40M option exercise payment.
- Sentynl (Zydus sub) option for alvelestat U.S. rights: $40M upfront/R&D on exercise, up to $435M milestones, double-digit royalties.
- Setrusumab Phase 3 missed primary fracture endpoint but hit key secondary BMD and PRO endpoints; FDA/MHRA discussions ongoing.
- Phase 3 alvelestat trial planned for early 2027 if option exercised.

## SEC filing metadata
- accession: 0001193125-26-343519
- form_type: 8-K
- ticker: MREO
- cik: 0001719714
- company_name: Mereo BioPharma Group plc
- filed_at: 2026-08-11T12:26:13+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719714/000119312526343519/0001193125-26-343519-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719714/000119312526343519/mreo-20260811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-343519
- JSON: https://secwatch.observer/filing/0001193125-26-343519.json
- Plain text: https://secwatch.observer/filing/0001193125-26-343519.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.